Pharmacokinetics and dosimetry of 111In/ 188 re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 3, 2011, Pages 373-380

  Lin, Yi Yu ^a   Chang, Chih Hsien ^a,b   Li, Jia Je ^a   Stabin, Michael G ^c   Chang, Ya Jen ^b   Chen, Liang Cheng ^b   Lin, Ming Hsien ^a,d   Tseng, Yun Long ^e   Lin, Wuu Jyh ^b   Lee, Te Wei ^b   Ting, Gann ^f   Chang, Cheng Allen ^a   Chen, Fu Du ^g   Wang, Hsin Ell ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^c VANDERBILT UNIVERSITY   (United States)

^d TAIPEI CITY HOSPITAL   (Taiwan)

^e Taiwan Liposome Company   (Taiwan)

^f NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^g TRANSWORLD UNIVERSITY   (Taiwan)

Author keywords

C26; dosimetry; doxorubicin; PEGylated liposomes; radionuclide therapy; vinorelbine

Indexed keywords

DOXORUBICIN; DOXORUBICIN RE 188; INDIUM 111; LIPOSOME; NAVELBINE; RHENIUM 188; UNCLASSIFIED DRUG; VINORELBINE IN 111;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; COLON CARCINOMA; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; ENCAPSULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; SOLID TUMOR;

ANIMALS; CELL LINE, TUMOR; COLONIC NEOPLASMS; HUMANS; INDIUM RADIOISOTOPES; INFUSIONS, PARENTERAL; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; POLYETHYLENE GLYCOLS; RADIOISOTOPES; RADIOMETRY; RHENIUM; TISSUE DISTRIBUTION;

EID: 79960048497     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2010.0906     Document Type: Article

References (41)

1. Markman M. Intraperitoneal chemotherapy in the management of colon cancer. Semin Oncol 1999;26:536.
2. Kanellos I, Demetriades H, Zintzaras E, et al. Incidence and prognostic value of positive peritoneal cytology in colorectal cancer. Dis Colon Rectum 2003;46:535.
3. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006;5:649.
4. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818.
5. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145.
6. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42:419.
7. Chang YJ, Chang CH, Yu CY, et al. Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model. Nucl Med Biol 2010;37:95.
8. Chen LC, Chang CH, Yu CY, et al. Pharmacokinetics, micro- SPECT/CT imaging and therapeutic efficacy of 188Re-DXRliposome in C26 colon carcinoma ascites mice model. Nucl Med Biol 2008;35:883.
9. Chang CH, Stabin MG, Chang YJ, et al. Comparative dosimetric evaluation of nanotargeted 188Re-(DXR)-liposome for internal radiotherapy. Cancer Biother Radiopharm 2008;23:749.
10. Lin YY, Li JJ, Chang CH, et al. Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ ascites mouse model. Cancer Biother Radiopharm 2009;24: 453.
11. Sadzuka Y, Hirota S, Sonobe T. Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination. Toxicol Lett 2000;116:51.
12. Cabanes A, Tzemach D, Goren D, et al. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res 1998;4:499.
13. Vaage J, Donovan D, Mayhew E, et al. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993;72:3671.
14. Uusijarvi H, Bernhardt P, Ericsson T, et al. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution. Med Phys 2006;33:3260.
15. Chow TH, Lin YY, Hwang JJ, et al. Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. J Nucl Med 2009;50:2073.
16. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004;3:488.
17. Kereiakes JG, Rao DV. Auger electron dosimetry: report of AAPM Nuclear Medicine Committee Task Group No. 6. Med Phys 1992;19:1359.
18. Chow TH, Lin YY, Hwang JJ, et al. Diagnostic and therapeutic evaluation of 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model. Nucl Med Biol 2008;35:623.
19. Sgouros G. Dosimetry of internal emitters. J Nucl Med 2005;46 Suppl 1:18S.
20. Measurements ICoRUa. Absorbed-Dose Specification in Nuclear Medicine, ICRU Report 67. J ICRU 2002;2:15.
21. Emfietzoglou D, Kostarelos K, Sgouros G. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med 2001;42:499.
22. ODonoghue JA, Baidoo N, Deland D, et al. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. Cancer Biother Radiopharm 2002;17:435.
23. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023.
24. Chang YJ, Chang CH, Chang TJ, et al. Biodistribution, pharmacokinetics and MicroSPECT/CT imaging of 188Re- BMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res 2007;27:2217.
25. Chen LC, Chang CH, Yu CY, et al. Biodistribution, pharmacokinetics and imaging of 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol 2007;34:415.
26. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys 2003;85:294.
27. Molina-Trinidad EM, de Murphy CA, Ferro-Flores G, et al. Radiopharmacokinetic and dosimetric parameters of 188Relanreotide in athymic mice with induced human cancer tumors. Int J Pharm 2006;310:125.
28. Bao A, Goins B, Klipper R, et al. 186Re-liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med 2003;44:1992.
29. Kostarelos K, Emfietzoglou D. Tissue dosimetry of liposomeradionuclide complexes for internal radiotherapy: toward liposome-targeted therapeutic radiopharmaceuticals. Anticancer Res 2000;20:3339.
30. Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Influence of tumour size on uptake of 111ln-DTPA-labelled pegylated liposomes in a human tumour xenograft model. Br J Cancer 2000;83:684.
31. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008;5:496.
32. Chow TH, Lin YY, Hwang JJ, et al. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/ luc xenografted mouse model. Anticancer Res 2009;29: 2111.
33. Bernhardt P, Ahlman H, Forssell-Aronsson E. Model of metastatic growth valuable for radionuclide therapy. Med Phys 2003;30:3227.
34. ODonoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med 1999;40:1337.
35. Pandit-Taskar N, ODonoghue JA, Morris MJ, et al. Antibody mass escalation study in patients with castrationresistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med 2008;49:1066.
36. Reilly RM, Chen P, Wang J, et al. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: An auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med 2006;47:1023.
37. Cremonesi M, Ferrari M, Bodei L, et al. Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med 2006; 47:1467.
38. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti- B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974.
39. Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol 2003;30:31.
40. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109.
41. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990; 18:1261.